Monitor for IND submission filing in Q3 2026 and Phase 1 initiation in Q4 2026 as the next key catalysts. No stock-moving event today; the update is routine corporate communication.
Price Chart
Executive Summary
Ernexa Therapeutics released a CEO Corner video discussing ERNA-101, its lead cell therapy candidate for ovarian cancer, highlighting preclinical data showing complete tumor clearance and 100% long-term survival in models when combined with PD-1 blockade. The company reiterated plans for an IND submission in Q3 2026 and first-in-human Phase 1 study in Q4 2026. No new material regulatory or financial event was disclosed.
Key Facts
- IND submission for ERNA-101 planned for Q3 2026
- First-in-human Phase 1 study anticipated to begin in Q4 2026
- Preclinical data demonstrated complete tumor clearance and 100% long-term survival in ovarian cancer models when combined with PD-1 blockade
- Proprietary off-the-shelf iMSC platform aimed at scalable manufacturing
- Market cap approximately $6M; pre-revenue clinical-stage biotech
Financial Impact
No financial figures disclosed; pre-revenue company with no reported revenue or earnings
Risk Factors
- Preclinical results may not translate to clinical efficacy
- Regulatory delays or IND clinical hold could push timelines
- Limited cash runway with $6M market cap; potential need for dilutive financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3326943 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $2.08 | awaiting T+5 | — | $1.96 (−5.54%) |
Oct 15, 2026 11d ago | 8-K | $2.09 $2.07 | ▼ −1.20% | ▼ −0.77% | $1.96 (−6.22%) |
Oct 1, 2026 26d ago | Press Release | $2.96 $2.49 | ▼ −15.88% | ▼ −17.18% | $1.96 (−33.78%) |
Sep 30, 2026 27d ago | Press Release | $3.20 $2.39 | ▼ −25.31% | ▼ −27.23% | $1.96 (−38.75%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $1.96 (−47.87%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $1.96 (−47.87%) |
Jul 14, 2026 15w ago | Press Release | $6.06 $5.43 | ▼ −10.40% | ▼ −9.10% | $1.96 (−67.66%) |
Jun 26, 2026 17w ago | 8-K | $7.03 $6.44 | ▼ −8.39% | ▼ −9.78% | $1.96 (−72.12%) |
Jun 17, 2026 18w ago | Press Release | $5.89 $6.30 | ▲ +6.96% | ▲ +8.00% | $1.96 (−66.72%) |
May 27, 2026 21w ago | Press Release | $11.14 $8.00 | ▼ −28.19% | ▼ −29.39% | $1.96 (−82.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers